Trial Outcomes & Findings for Subcuticular Suture for Cesarean Skin Incision Closure (NCT NCT02459093)

NCT ID: NCT02459093

Last Updated: 2018-06-01

Results Overview

Any wound disruption, fluid accumulation, separation, all CDC defined stages of surgical site infection (SSI)

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

550 participants

Primary outcome timeframe

30 days

Results posted on

2018-06-01

Participant Flow

Participant milestones

Participant milestones
Measure
Poliglecaprone 25 Suture
Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery poliglecaprone 25 suture: cesarean delivery incision closure with poliglecaprone 25 suture
Polyglactin 910 Suture
Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery polyglactin 910 suture: cesarean delivery incision closure with polyglactin 910 suture
Overall Study
STARTED
275
275
Overall Study
COMPLETED
263
257
Overall Study
NOT COMPLETED
12
18

Reasons for withdrawal

Reasons for withdrawal
Measure
Poliglecaprone 25 Suture
Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery poliglecaprone 25 suture: cesarean delivery incision closure with poliglecaprone 25 suture
Polyglactin 910 Suture
Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery polyglactin 910 suture: cesarean delivery incision closure with polyglactin 910 suture
Overall Study
Protocol Violation
6
11
Overall Study
Lost to Follow-up
6
7

Baseline Characteristics

Subcuticular Suture for Cesarean Skin Incision Closure

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Poliglecaprone 25 Suture
n=263 Participants
Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery poliglecaprone 25 suture: cesarean delivery incision closure with poliglecaprone 25 suture
Polyglactin 910 Suture
n=257 Participants
Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery polyglactin 910 suture: cesarean delivery incision closure with polyglactin 910 suture
Total
n=520 Participants
Total of all reporting groups
Age, Continuous
31.4 years
STANDARD_DEVIATION 5.4 • n=5 Participants
31.2 years
STANDARD_DEVIATION 5.4 • n=7 Participants
31.3 years
STANDARD_DEVIATION 5.4 • n=5 Participants
Sex: Female, Male
Female
263 Participants
n=5 Participants
257 Participants
n=7 Participants
520 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race/Ethnicity, Customized
White
18 Participants
n=5 Participants
17 Participants
n=7 Participants
35 Participants
n=5 Participants
Race/Ethnicity, Customized
African American
64 Participants
n=5 Participants
61 Participants
n=7 Participants
125 Participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic
128 Participants
n=5 Participants
130 Participants
n=7 Participants
258 Participants
n=5 Participants
Race/Ethnicity, Customized
Asian
17 Participants
n=5 Participants
11 Participants
n=7 Participants
28 Participants
n=5 Participants
Race/Ethnicity, Customized
Other
14 Participants
n=5 Participants
26 Participants
n=7 Participants
40 Participants
n=5 Participants
Race/Ethnicity, Customized
Missing
22 Participants
n=5 Participants
12 Participants
n=7 Participants
34 Participants
n=5 Participants
Cesarean delivery with labor
Scheduled or no labor
224 Participants
n=5 Participants
207 Participants
n=7 Participants
431 Participants
n=5 Participants
Cesarean delivery with labor
Any labor
39 Participants
n=5 Participants
50 Participants
n=7 Participants
89 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 30 days

Population: Intent to treat analysis

Any wound disruption, fluid accumulation, separation, all CDC defined stages of surgical site infection (SSI)

Outcome measures

Outcome measures
Measure
Poliglecaprone 25 Suture
n=263 Participants
Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery poliglecaprone 25 suture: cesarean delivery incision closure with poliglecaprone 25 suture
Polyglactin 910 Suture
n=257 Participants
Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery polyglactin 910 suture: cesarean delivery incision closure with polyglactin 910 suture
Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)
Composite wound
23 Participants
37 Participants
Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)
Surgical Site Infection
16 Participants
25 Participants
Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)
Hematoma
1 Participants
3 Participants
Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)
Seroma
2 Participants
1 Participants
Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)
Separation
7 Participants
13 Participants

PRIMARY outcome

Timeframe: 30 days

Population: As treated

Any wound disruption, fluid accumulation, separation, all CDC defined stages of surgical site infection (SSI)

Outcome measures

Outcome measures
Measure
Poliglecaprone 25 Suture
n=265 Participants
Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery poliglecaprone 25 suture: cesarean delivery incision closure with poliglecaprone 25 suture
Polyglactin 910 Suture
n=217 Participants
Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery polyglactin 910 suture: cesarean delivery incision closure with polyglactin 910 suture
Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)
Composite wound
22 Participants
30 Participants
Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)
Surgical Site Infection
16 Participants
20 Participants
Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)
Hematoma
1 Participants
2 Participants
Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)
Seroma
1 Participants
2 Participants
Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)
Separation
8 Participants
8 Participants

Adverse Events

Poliglecaprone 25 Suture

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Polyglactin 910 Suture

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr David Garry

Stony Brook Medicine

Phone: 631-444-7650

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place